等待开盘 05-12 09:30:00 美东时间
+0.030
+0.11%
Oppenheimer analyst Suraj Kalia downgrades AtriCure (NASDAQ:ATRC) from Outperform to Perform.
02-18 19:39
AtriCure (NASDAQ:ATRC) is looking for FY2026 GAAP EPS of $0.01-$0.04 vs $(0.04) analyst estimate..
02-18 06:00
2026 Financial GuidanceManagement projects 2026 revenue of approximately $600 million to $610 million, reflecting growth of approximately 12% to 14% over full year 2025. Management also projects full year positive
01-12 23:25
北京时间2025年01月16日03时41分,AtriCure(ATRC.us)股票出现波动,股价快速拉升5.04%。截至发稿,该股报36.44美元/股,成交量25.8045万股,换手率0.53%,振幅4.67%。 最近的财报数据显示,该股实现营业收入1.16亿美元,净利润-7.85百万美元,每股收益-0.17美元,毛利86.03百万美元,市盈率-43.83倍。 机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。 AtriCure股票所在的医疗设备行业中,整体涨幅为4.12%。其相关个股中,Microbot Medical Inc.、Nexgel, Inc、Nephros, Inc....
2025-01-16 03:41
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip® FLEX-Mini™ device, which recently receive...
2024-08-27 20:04
09:29 AM EDT, 08/22/2024 (MT Newswires) -- AtriCure (ATRC) said Thursday it has received an expanded indication in CE-marked countries in Europe for the AtriClip device. The product can now be used in patients at "high risk" of thromboembolism for whom left atrial appendage exclusion is warranted, t...
2024-08-22 21:29